

Pharmacy and Therapeutics Committee State of Nevada Department of Health and Human Services Division of Health Care Financing and Policy 1100 E. William St. Ste. 101 Carson City N.V. 89701

Re: Agenda Item 5.f., Discussion and possible adoption of psychotropic agents-Antipsychotics-atypical antipsychotics, oral.I

To whom it may concern:

I understand that Nevada Medicaid will review oral atypical antipsychotics for the preferred drug list at the December 9th, 2021, Therapeutics Committee meeting. I will request that the committee will add Caplyta (lumateperone) to the State of Nevada formulary for Schizophrenia.

We have a number of patients using Caplyta with schizophrenia currently receiving treatment at our clinic. We have noticed our patients have responded in a positive manner. Patients have become more organized, and have been functioning with daily routines positively. My patients have gained little weight with very little metabolic changes. One of our patients has reduced the number of visits to the clinic since commencing Caplyta.

We appreciate the consideration in adding this important new medication to the state of Nevada Formulary.

Uzoma Osuchukwu, MD, MPH.

Office: 702.763.7811 Fax: 702.947.4920 4310 W. Cheyenne Ave. North Las Vegas, Nv. 89032 www.advancedpsychiatryinc.com